Zarinara 2010.

Methods	A 6‐week double‐blind, parallel‐group randomised clinical trial with 2 arms: Methylphenidate Venlafaxine No control/no‐intervention group
Participants	Number of participants screened: 60 Number of participants included: 38 Number randomised to methylphenidate: 19 Number of participants followed up in the methylphenidate group: 18 Number of withdrawals in the methylphenidate group: 1 MPH group Diagnosis of ADHD: DSM‐IV‐TR (subtype: combined (100%)) Age: mean 9.57 years old (range 6‐13) IQ: above 70 Sex: 13 males, 6 females Methylphenidate‐naïve: 100% (newly diagnosed) Ethnicity: Persian (100%) Country: Iran Comorbidity: not stated Comedication: not stated Sociodemographics: not stated Inclusion criteria: 6‐13 years old Diagnosis of ADHD according to DSM‐IV‐TR Total or subscale scores (or both) on ADHD‐RS‐IV: School Version of ≥ 1.5 SD above norms for patient's age and gender To participate, parents and children had to be willing to comply with all requirements of the study Exclusion criteria: A history or current diagnosis of pervasive developmental disorders, schizophrenia, or other psychiatric disorders (DSM‐IV axis I) Any current psychiatric comorbidity that required pharmacotherapy Any evidence of suicide risk and mental retardation (IQ below 70) A clinically significant chronic medical condition, including organic brain disorder, seizures, or current abuse or dependence on drugs the last 6 months Hypertension or hypotension
Interventions	Methylphenidate type: not stated Methylphenidate dosage: 20‐30 mg/day depending on weight (20 mg/day for < 30 kg and 30 mg/day for > 30 kg) Methylphenidate titration: 3 weeks (week 1: 10 mg/day twice daily; week 2: 20 mg/day twice daily; and week 3: 30 mg/day for children > 30 kg 3 times daily) Duration of intervention: 6 weeks inclusive titration Treatment compliance: not stated
Outcomes	Adverse effects checklist (20 possible adverse events), rated by a child psychiatrist on days 7, 21, 42. Body weight and vital signs assessed at baseline, week 1, 2, 4, 6. 12‐lead ECG and physical examination at baseline and week 6
Notes	Sample calculation: not stated Ethics approval: yes Funding/vested interests/authors' affiliations: this study was supported by a grant from Tehran University of Medical Sciences Key conclusions of the study authors: the results suggest that venlafaxine may be useful for the treatment of ADHD. In addition, a tolerable side‐effect profile is one of the advantages of venlafaxine in the treatment of ADHD Exclusion of methylphenidate non‐responders/children who have previously experienced adverse events on methylphenidate: no Supplemental information regarding data requested through personal communication with the authors in August 2013. No reply